

Grants Awarded through the Expression of Interest Process

1 January 2015 to 30 June 2016

Antiviral Targets

Professor Paul Gorry. Burnet Institute. Second Generation CCR5 Antagonists as New HIV-1 Entry Inhibitors.

Dr. Karla Helbig. University of Adelaide. Targeting HBV cccDNA using the CRISPR/cas system.

Professor Paul Hertzog. Monash University. Blocking HIV transmission via supplementation of interferon epsilon.

Professor David A. Jans. Monash University. New Inhibitors for HIV

Professor Michael Jennings. Griffith University. Defining the HIV glycointeractome: a novel antiviral target.

Professor Phillip Robinson. Children's Medical Research Institute. Inhibition of dynamin II (DynII) as a novel HIV therapeutic and microbicide strategy.

Dr. Con Sonza. The University of Melbourne. Targeting Splicing in Latently Infected T cells to contribute to a cure for HIV.

Dr. Thomas Tu. University of Sydney. Developing a humanised mouse model for testing HBV cccDNA-targeting therapies.

Diagnostics / Prognostics

Dr. Brigid Betz-Stablein. The University of New South Wales. Tools for high-throughput detection of mixed infection and recombination in HCV.

Dr. Rowena Bull. The University of New south Wales. Novel markers for the prediction of hepatitis C virus clearance.

Dr. Lachlan R. Gray. Burnet Institute. Clinically validating the first suite of genotypic prognostic tropism tests for non-b-HIV-1 subtypes.

Dr Anna Hearps. Burnet Institute. Mapping the HIV reservoir in monocytes and macrophages

Professor Johnson Mak. Deakin University. Quantify HIV-1 latent reservoir that has a handful of HIV-1 mRNA.

Dr. Clovis S Palmer. Burnet Institute. Prognostic tools to improve the clinical care of people living with HIV infection.

Associate Professor Sarah Palmer. Westmead Millennium Institute. Longitudinal assessment of the relationship between immune activation and HIV persistence.

Associate Professor Edwina Wright. Monash University. The START HIV-1 reservoir substudy.

Vaccines

Dr. Fasseli Coulibaly. Monash University. HIV MicroCubes: towards a multi-antigen, cross-protective vaccine

Dr. Heidi Drummer. Burnet Institute. Analytical tools for GLP and GMP manufacture of a novel HCV vaccine candidate, Delta3™.

Professor Stephen Kent. University of Melbourne. Antibody protection and therapy for HIV.

Dr. Pantelis Poubourios. Burnet Institute. Novel HIV-like particle and recombinant glycoprotein vaccines with enhanced presentation of broad neutralization epitopes

Dr. Charani Ranasinghe. The Australian National University. Pre-clinical evaluation of a novel mucosal HIV vaccine strategy.

Dr. Di Yu. Monash University. Humanisation and validation of a superagonist antibody to human IL-21 for a novel immunotherapy to eliminate chronic viral infections.